An artificial intelligence (AI)-enabled platform that can reportedly diagnose heart failure with preserved ejection fraction (HFpEF) through analysis of a single echocardiogram view, the EchoGo Heart Failure now has a HCPCS code for use of the technology in outpatient settings for Medicare beneficiaries.
A newly issued HCPCS code from the Centers for Medicare and Medicaid Services (CMS) may facilitate wider adoption and reimbursement for use of the artificial intelligence (AI)-enabled EchoGo® Heart Failure device (Ultromics) to aid in detecting heart failure with preserved ejection fraction (HFpEF).
Clinicians may utilize the HCPCS code (C9786), which went into effect on July 1, 2023, for “computer-aided detection” of HFpEF based on echocardiography images, according to CMS.1 Ultromics noted the HCPCS code is designated for outpatient use of the EchoGo® Heart Failure device for Medicare beneficiaries.
“This is a major milestone and will enable hospitals to accelerate the adoption of EchoGo Heart Failure to improve detection of HFpEF within their systems,” noted Ross Upton, Ph.D., the CEO and founder of Ultromics. “Given the prevalence of HFpEF, this is a significant development toward recognizing and detecting a heavily underdiagnosed condition.”
EchoGo Heart Failure, which received FDA 510(k) clearance in December 2022, provides automated detection of HFpEF through AI assessment of a single view of an echocardiogram, according to Ultromics.2 The company noted that recently published research has demonstrated an 87.8 percent sensitivity rate and an 83 percent specificity rate for EchoGo Heart Failure in the diagnosis of HFpEF.3,4
References
1. Ultromics. CMS establishes HCPCS code for Ultromics EchoGo Heart Failure, accelerating access to precision HFpEF detection. Available at: https://www.prnewswire.com/news-releases/cms-establishes-hcpcs-code-for-ultromics-echogo-heart-failure-accelerating-access-to-precision-hfpef-detection-301869759.html . Published July 5, 2023. Accessed July 6, 2023.
2. Hall J. FDA clears AI-powered echocardiography platform for detecting heart failure with preserved ejection fraction. Diagnostic Imaging. Available at: https://www.diagnosticimaging.com/view/fda-clears-ai-powered-echocardiography-platform-for-detecting-heart-failure-with-preserved-ejection-fraction . Published December 7, 2022. Accessed July 6, 2023.
3. Nikorowitsch J, Bei der Kellen J, Kirchhof P, et al. Applying the ESC 2016, H2 FPEF, and HFA-PEFF diagnostic algorithms for heart failure with preserved ejection fraction to the general population. ESC Heart Fail. 2021;8(5):3603-3612.
4. Sanders-van Wijk S, Aizpurua AB, Brunner-La Rocca HP, et al. The HFA-PEFF and H2FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction. Eur J Heart Fail. 2021;23(5):838-840.
Could AI-Powered Abbreviated MRI Reinvent Detection for Structural Abnormalities of the Knee?
April 24th 2025Employing deep learning image reconstruction, parallel imaging and multi-slice acceleration in a sub-five-minute 3T knee MRI, researchers noted 100 percent sensitivity and 99 percent specificity for anterior cruciate ligament (ACL) tears.
The Reading Room Podcast: Emerging Trends in the Radiology Workforce
February 11th 2022Richard Duszak, MD, and Mina Makary, MD, discuss a number of issues, ranging from demographic trends and NPRPs to physician burnout and medical student recruitment, that figure to impact the radiology workforce now and in the near future.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.